| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bruce J Kirenga, Levicatus Mugenyi, Marina S\\xc3\\xa1nchez-Rico, Henry Kyobe, Winters Muttamba, Raymond Mugume, Eliya Mwesigwa, Ezra Kalimo, Vicky Nyombi, Ivan Segawa, Loryndah Olive Namakula, Rogers Sekibira, Wilberforce Kabweru, Rosemary Byanyima, Hellen Aanyu, Pauline Byakika-Kibwika, Henry G Mwebesa, Nicolas Hoertel, William Bazey. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Molecular psychiatry vol issue 2023 36869228 |
prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (ssri) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against covid-19. |
2023-03-03 |
2023-03-06 |
Not clear |
| \\xc5\\x9eeng\\xc3\\xbcl Kocamer \\xc5\\x9eahin, Bahadir Demir, Abdurrahman Altinda\\xc4\\x9. Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report. International clinical psychopharmacology vol issue 2023 36752695 |
first-line drugs for obsessive-compulsive disorder (ocd) pharmacotherapy are selective serotonin reuptake inhibitors (ssri). |
2023-02-08 |
2023-03-06 |
Not clear |
| Naoki Amada, Tsuyoshi Hirose, Mikio Suzuki, Yusuke Kakumoto, Takashi Futamura, Kenji Maeda, Tetsuro Kikuch. Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology reports vol issue 2023 36649966 |
selective serotonin reuptake inhibitors (ssris) are used to treat major depressive disorder (mdd) and other psychiatric disorders (e.g., obsessive compulsive disorder, social anxiety disorder, and panic disorder). |
2023-01-17 |
2023-01-30 |
mouse |
| Peter J van Roessel, Giacomo Grassi, Elias N Aboujaoude, Jos\\xc3\\xa9 M Mench\\xc3\\xb3n, Michael Van Ameringen, Carolyn I Rodr\\xc3\\xadgue. Treatment-resistant OCD: Pharmacotherapies in adults. Comprehensive psychiatry vol 120 issue 2022 36368186 |
serotonin reuptake inhibitor (sri) medications are well established as first-line pharmacotherapeutic treatment for obsessive-compulsive disorder (ocd). |
2022-11-11 |
2023-01-30 |
Not clear |
| J\\xc3\\xa9ssica Fernandes da Silva, Leticia Mitsuko Taguchi, Erinete da Silva Leite, Amanda Ribeiro de Oliveir. mCPP-induced behavioral changes in OCD research: a systematic review of rodent studies. Neuroscience vol issue 2022 36332691 |
meta-chlorophenylpiperazine (mcpp) was one of the first compounds used in clinical and preclinical studies that demonstrated the role of serotonin in obsessive-compulsive disorder (ocd). |
2022-11-04 |
2023-01-30 |
rat |
| Xiao-Lin Li, Shan-Qing Huang, Tao Xiao, Xi-Pei Wang, Wan Kong, Shu-Jing Liu, Zi Zhang, Ye Yang, Shan-Shan Huang, Xiao-Jia Ni, Hao-Yang Lu, Ming Zhang, Yu-Guan Wen, De-Wei Shan. Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients. Frontiers in pharmacology vol 13 issue 2022 36172189 |
paroxetine is one of the most potent selective serotonin reuptake inhibitors (ssris) approved for treating depression, panic disorder, and obsessive-compulsive disorder. |
2022-09-29 |
2023-01-30 |
Not clear |
| John Lz Nyirenda, Mario Sofroniou, Ingrid Toews, Agata Mikolajewska, Cornelius Lehane, Ina Monsef, Aesha Abu-Taha, Andy Maun, Miriam Stegemann, Christine Schmucke. Fluvoxamine for the treatment of COVID-19. The Cochrane database of systematic reviews vol 9 issue 2022 36103313 |
fluvoxamine is a selective serotonin reuptake inhibitor (ssri) that has been approved for the treatment of depression, obsessive-compulsive disorder, and a variety of anxiety disorders; it is available as an oral preparation. |
2022-09-14 |
2023-01-30 |
Not clear |
| Luca Pellegrini, Kabir Garg, Arun Enara, David Shimon Gottlieb, David Wellsted, Umberto Albert, Keith R Laws, Naomi A Fineber. Repetitive transcranial magnetic stimulation (r-TMS) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: A meta-analysis and clinical implications. Comprehensive psychiatry vol 118 issue 2022 35917621 |
repetitive transcranial magnetic stimulation (r-tms) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: a meta-analysis and clinical implications. |
2022-08-02 |
2023-01-30 |
Not clear |
| Ahmed Naguy, Anubhuti Singh, Fajer Q M AlDarweesh, Bibi Alamir. Possible Toxic Serotonin Syndrome in an Adolescent With Obsessive-Compulsive Disorder Precipitated by Esomeprazole. The primary care companion for CNS disorders vol 24 issue 4 2022 35878563 |
possible toxic serotonin syndrome in an adolescent with obsessive-compulsive disorder precipitated by esomeprazole. |
2022-07-25 |
2023-01-30 |
Not clear |
| Christiana Bratiotis, Jordana Muroff, Nancy X Y Li. Hoarding Disorder: Development in Conceptualization, Intervention, and Evaluation. Focus (American Psychiatric Publishing) vol 19 issue 4 2022 35747296 |
cognitive-behavioral therapy (cbt) with exposure and response prevention and selective serotonin reuptake inhibitor medications traditionally used to treat obsessive-compulsive disorder are generally not efficacious for people with hoarding problems. |
2022-06-24 |
2023-01-27 |
Not clear |
| Pei Wang, Wenjie Gu, Jian Gao, Changhong Wang, Jianqun Fang, Maorong Hu, Hui Xiang, Bin Li, Na Liu, Wenxin Tang, Xijin Wang, Yanbin Jia, Yi Li, Yuqi Cheng, Zhen Tang, Helen Blair Simpson, Dan J Stein, Zhen Wan. Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in psychiatry vol 13 issue 2022 35651818 |
selective serotonin reuptake inhibitors (ssris) are the first-line pharmacotherapy for obsessive-compulsive disorder (ocd), but a large proportion of patients do not achieve remission after an adequate ssri trial. |
2022-06-02 |
2023-01-27 |
Not clear |
| Miaohan Deng, Yuan Wang, Shunying Yu, Qing Fan, Jianyin Qiu, Zhen Wang, Zeping Xia. Exploring Association Between Serotonin and Neurogenesis Related Genes in Obsessive-Compulsive Disorder in Chinese Han People: Promising Association Between DMRT2, miR-30a-5p, and Early-Onset Patients. Frontiers in psychiatry vol 13 issue 2022 35633798 |
exploring association between serotonin and neurogenesis related genes in obsessive-compulsive disorder in chinese han people: promising association between dmrt2, mir-30a-5p, and early-onset patients. |
2022-05-31 |
2023-01-27 |
Not clear |
| Satish Suhas, Palash Kumar Malo, Vijay Kumar, Thomas Gregor Issac, Nellai K Chithra, Binukumar Bhaskarapillai, Y C Janardhan Reddy, Naren P Ra. Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomized controlled trials. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry vol issue 2022 35615998 |
treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a network meta-analysis of randomized controlled trials. |
2022-05-26 |
2023-01-27 |
Not clear |
| Jasmine Brar, Ajeet Sidana, Nidhi Chauhan, Manoj Kumar Baja. A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder. Journal of psychiatric research vol 151 issue 2022 35598501 |
a randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder. |
2022-05-22 |
2023-01-27 |
Not clear |
| Che Yu Kuo, Kao Chin Chen, I Hui Lee, Huai-Hsuan Tseng, Nan Tsing Chiu, Po See Chen, Yen Kuang Yang, Wei Hung Chan. Serotonin Modulates the Correlations between Obsessive-compulsive Trait and Heart Rate Variability in Normal Healthy Subjects: A SPECT Study with [ Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol 20 issue 2 2022 35466098 |
serotonin modulates the correlations between obsessive-compulsive trait and heart rate variability in normal healthy subjects: a spect study with [ the impact of serotonergic system on obsessive-compulsive disorder (ocd) is well studied. |
2022-04-25 |
2023-01-27 |
human |
| Antonio Tundo, Loretta Salvati, Luca Cieri, Viviana Balestrini, Daniela Di Spigno, Floriana Orazi, Marica Iommi, Roberta Necc. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study. International journal of psychiatry in clinical practice vol issue 2022 35323098 |
serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. |
2022-03-24 |
2023-01-27 |
Not clear |
| Antonio Tundo, Loretta Salvati, Luca Cieri, Viviana Balestrini, Daniela Di Spigno, Floriana Orazi, Marica Iommi, Roberta Necc. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study. International journal of psychiatry in clinical practice vol issue 2022 35323098 |
six in ten patients with obsessive-compulsive disorder (ocd) do not respond to the first-line treatments with serotonin reuptake inhibitor (sri) or cognitive behavioural therapy including exposure and response prevention (cbt/erp), and several do not respond to second-line treatments, i.e., sri-second generation antipsychotic (sga) or sri-cbt/erp augmentation. |
2022-03-24 |
2023-01-27 |
Not clear |
| Igor D Bandeira, Daniel H Lins-Silva, Vitor Breseghello Cavenaghi, Ingrid Dorea-Bandeira, Daniela Faria-Guimar\\xc3\\xa3es, Judah L Barouh, Ana Paula Jesus-Nunes, Graziele Beanes, Lucca S Souza, Gustavo C Leal, Gerard Sanacora, Euripedes C Miguel, Aline S Sampaio, Lucas C Quarantin. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard review of psychiatry vol 30 issue 2 2022 35267254 |
first-line treatment for obsessive-compulsive disorder (ocd) includes exposure and response prevention behavioral therapy and serotonin reuptake inhibitors, particularly in combination. |
2022-03-10 |
2023-01-27 |
Not clear |
| Najmeh Shahini, Ali Talaei, Mohammadreza Shalbafan, Farhad Faridhosseini, Maliheh Ziae. Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder. Basic and clinical neuroscience vol 12 issue 4 2022 35154589 |
effects of celecoxib adjunct to selective serotonin reuptake inhibitors on obsessive-compulsive disorder. |
2022-02-14 |
2023-01-27 |
Not clear |
| Faezeh Nikzad, Seyed Alireza Sadjadi, Amir Hooshang Mohammadpour, Maliheh Ziaee, Fatemeh Behdani, Seyedeh Maryam Naghibi, Seyedeh Narges Nejatifard, Mahdieh Ghanbari, Ali Akhondpour Mantegh. Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs). Iranian journal of psychiatry vol 16 issue 4 2022 35082857 |
adjunct triptorelin in the treatment of obsessive-compulsive disorder in clients receiving selective serotonin reuptake inhibitors (ssris). |
2022-01-27 |
2023-01-27 |
Not clear |